Drug intelligence / Profile preview

Phytopica (Phytopharm plc)

Development stage: Preclinical
Lead developer: Phytopharm
Administration: Oral

Overview

**Phytopica** is an oral veterinary botanical product originally developed by Phytopharm for canine skin health and atopic dermatitis. It is a proprietary, chemically heterogeneous blend of standardized plant extracts rather than a single defined molecular entity. In a randomized, double-blind, placebo-controlled 12-week study in 120 dogs with perennial canine atopic dermatitis, the product code **PYM00217** produced a statistically significant reduction in CADESI disease-severity scores at 200 mg/kg/day; no serious adverse effects were reported, although mild gastrointestinal events occurred more frequently at higher doses. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16827666/))

Brand names: Phytopica

Beyond the preview

Go deeper on Phytopica (Phytopharm plc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phytopica (Phytopharm plc).

Explore the full profile